title: Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of nedaplatin (NDP) concurrent with radiotherapy in the treatment of locally advanced esophageal carcinoma.
  
  
  METHODS
  Sixty-eight patients with locally advanced esophageal carcinoma were randomized into either a NDP group (n = 34) or a cisplatin (DDP) group (n = 34). The NDP group received NDP 80-100 mg/m² iv on day 1 + leucovorin (CF) 100 mg/m² iv on days 1-5 + 5-fluorouracil (5-FU) 500 mg/m² iv on days 1-5. The DDP group received DDP 30 mg/m² iv on days 1-3 + CF 100 mg/m² on days 1-5 + 5-FU 500 mg/m² iv on days 1-5. The treatment was repeated every 4 wk in both groups. Concurrent radiotherapy [60-66 Gy/(30-33 f)/(6-7 wk)] was given during chemotherapy.
  
  
  RESULTS
  There was no significant difference in the short-term response rate between the NDP group and DDP group (90.9% vs 81.3%, P = 0.528). Although the 1- and 2-year survival rates were higher in the NDP group than in the DDP group (75.8% vs 68.8%, 57.6% vs 50.0%), the difference in the overall survival rate was not statistically significant between the two groups (P = 0.540). The incidences of nausea, vomiting and nephrotoxicity were significantly lower in the NDP group than in the DDP group (17.6% vs 50.0%, P = 0.031; 11.8% vs 47.1%, P = 0.016; 8.8% vs 38.2%, P = 0.039). There was no significant difference in the incidence of myelosuppression, radiation-induced esophagitis or radiation-induced pneumonia between the two groups.
  
  
  CONCLUSIONS
  NDP-based concurrent chemoradiotherapy is effective and well-tolerated in patients with locally advanced esophageal carcinoma. NDP-based regimen has comparable efficacy to DDP-based regimen but is associated with lower incidences of gastrointestinal and renal toxicity.
authors.affiliation: Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.
authors.forename: Ze-Tian
authors.initials: ZT
authors.lastname: Shen
authors.affiliation: Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.
authors.forename: Xin-Hu
authors.initials: XH
authors.lastname: Wu
authors.affiliation: Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Li
authors.affiliation: Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.
authors.forename: Jun-Shu
authors.initials: JS
authors.lastname: Shen
authors.affiliation: Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.
authors.forename: Xi-Xu
authors.initials: XX
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D002681:China; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009944:Organoplatinum Compounds; C053989:nedaplatin; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil
keywords: Chemoradiotherapy; Cisplatin; Esophageal carcinoma; Nedaplatin